A new vaccine effectively reduced beta-amyloid (Aβ) and tau pathology in bigenic mice, by generating high Aβ- and tau-specific antibodies that led to significant reductions of both pathologies in the brain, supporting further development of this vaccine for testing in human Alzheimer’s disease.

A new vaccine effectively reduced beta-amyloid (Aβ) and tau pathology in bigenic mice, by generating high Aβ- and tau-specific antibodies that led to significant reductions of both pathologies in the brain, supporting further development of this vaccine for testing in human Alzheimer’s disease.: https://ift.tt/2SDuZVD Read more... https://ift.tt/2QziOGH